文献速递类风湿关节炎脊柱关节炎其他结缔组织病

JAK抑制剂与其他先进疗法在免疫介导炎症性疾病中的癌症风险:系统综述与贝叶斯网络荟萃分析

Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs.
PubMed 文献 · Ann Rheum Dis · 2026-07-10

该系统综述与贝叶斯网络荟萃分析纳入305项随机试验及长期扩展研究(164,824例受试者,264,100人年暴露),评估JAK抑制剂与其他先进疗法在RA、PsO/PsA及IBD中的恶性肿瘤风险。结果显示,JAK抑制剂相比TNF抑制剂(RR 1.60;95%CrI 1.27-2.02)和标准治疗(RR 1.85;95%CrI 1.38-2.47)均与更高的恶性肿瘤风险相关,绝对超额风险在标准风险人群中可忽略,但在高风险人群中具有临床意义。

要点

  • JAK抑制剂相比TNF抑制剂与标准治疗的恶性肿瘤风险均升高。
  • IL-6、IL-17、IL-23、IL-12/23、CTLA-4及CD20靶向疗法的风险与TNF抑制剂大致相当。
  • JAK抑制剂的绝对超额癌症风险在标准风险人群中可忽略,在高风险人群中具有临床意义。

核心结论

  • 在免疫介导炎症性疾病中,JAK抑制剂相比TNF抑制剂和标准治疗与更高的恶性肿瘤风险相关。
  • 该关联在RA、PsO/PsA和IBD网络中方向一致,提示监管警告应扩展至RA以外的疾病。

研究设计与样本

  • 系统检索MEDLINE、Embase、Cochrane Library和ClinicalTrials.gov(至2026年2月),纳入 licensed 先进疗法在成人RA、PsO/PsA或IBD中报告恶性肿瘤结局的II-IV期随机试验及长期扩展研究。
  • 采用泊松模型的贝叶斯类水平网络荟萃分析,估计与标准治疗(安慰剂或甲氨蝶呤单药)相比的发病率比(RR),纳入所有恶性肿瘤包括非黑色素瘤皮肤癌。
  • 共纳入305项研究(164,824例受试者;264,100人年暴露),包括174项跨IMIDs研究、123项RA研究、129项PsO/PsA研究和54项IBD研究。

主要发现

  • 在合并IMID网络中,JAK抑制剂相比TNF抑制剂与更高的恶性肿瘤风险相关(RR 1.60;95%CrI 1.27-2.02),相比标准治疗亦更高(RR 1.85;95%CrI 1.38-2.47)。
  • 在RA、PsO/PsA和IBD网络中观察到方向一致的发现。
  • IL-6、IL-17、IL-23、IL-12/23、CTLA-4、CD20靶向疗法的风险与TNF抑制剂大致相当。
  • JAK抑制剂相比TNF抑制剂的绝对超额癌症风险在标准风险人群中可忽略(+0.037例/1000人年暴露;约每27,000人年暴露增加1例癌症),但在高风险人群中具有临床意义(+6.814例/1000人年暴露;约每147人年暴露增加1例癌症)。

临床怎么用

  • 在免疫介导炎症性疾病中处方JAK抑制剂时,应进行风险分层的治疗决策,尤其关注高风险人群的恶性肿瘤风险。
  • 对于标准风险人群,JAK抑制剂相比TNF抑制剂的绝对超额癌症风险可忽略,但仍需权衡相对风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Oral Rheumatoid Arthritis Trial Surveillance trial identified increased malignancy risk with tofacitinib vs tumour necrosis factor inhibitors (TNFis) in rheumatoid arthritis (RA), leading to class-wide regulatory warnings for Janus kinase inhibitors (JAKis). Comparative cancer risk vs other advanced therapies and across immune-mediated inflammatory diseases (IMIDs) remains uncertain. The objective was to estimate relative and absolute cancer risk associated with JAKi vs other advanced therapies across IMIDs. METHODS: MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026 for phases II to IV randomised trials and long-term extension studies of licensed advanced therapies in adults with RA, psoriasis (PsO)/psoriatic arthritis (PsA), or inflammatory bowel disease (IBD) reporting malignancy outcomes. Bayesian class-level network meta-analyses using Poisson models estimated incidence rate ratios (RRs) vs standard care (placebo or methotrexate monotherapy). It includes all malignancies including nonmelanoma skin cancer. RESULTS: A total of 305 studies (164,824 participants; 264,100 person-years exposure) were included, comprising 174 studies across IMIDs, 123 in RA, 129 in PsO/PsA, and 54 in IBD. In the combined IMID network, JAKi were associated with higher malignancy risk than TNFi (RR: 1.60; 95% credible interval [CrI]: 1.27-2.02) and standard care (RR: 1.85; 95% CrI: 1.38-2.47). Similar directional findings were observed across RA, PsO/PsA, and IBD networks. Interleukin-6 (IL-6), Interleukin-17 (IL-17), Interleukin-23 (IL-23), Interleukin-12/23 (IL-12/23), Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), B-lymphocyte antigen CD20 (CD20)-targeting therapies showed risks broadly comparable with TNFi. Absolute excess cancer risk with JAKi compared with TNFi was negligible in standard-risk populations (+0.037 cancers per 1000 person-years exposure [PYE]; ∼1 additional cancer per 27,000 PYE) but meaningful in higher-risk populations (+6.814 cancers per 1000 PYE; ∼1 additional cancer per 147 PYE). CONCLUSIONS: Across IMIDs, JAKi were consistently associated with higher malignancy risk relative to TNFi and standard care, extending regulatory warnings beyond RA and emphasising the need for risk-stratified treatment decisions.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Gibson M, Allen V, Adas M, et al. Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs. Ann Rheum Dis. 2026. PMID: 42431784. doi:10.1016/j.ard.2026.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。